Search Site
Home >> Signaling Pathways >> TGF-β / Smad Signaling >> Bcr-Abl >> Saracatinib (AZD0530)
Related Products
Saracatinib (AZD0530)Src/Abl inhibitor,potent and selective

Saracatinib (AZD0530)

Catalog No. A2133
Size Price Stock Qty
10mM (in 1mL DMSO) $60.00 In stock
Evaluation Sample $28.00 In stock
5mg $50.00 In stock
25mg $120.00 In stock
100mg $300.00 In stock

Tel: +1-832-696-8203


Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Product Citations

1. Diao Y, Ma X, Min W, Lin S, Kang H, Dai Z, Wang X, Zhao Y. "Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src." Cancer Lett. 2016 May 16. PMID:27195913

Quality Control

Chemical structure

Saracatinib (AZD0530)

Related Biological Data

Saracatinib (AZD0530)

Related Biological Data

Saracatinib (AZD0530)

Related Biological Data

Saracatinib (AZD0530)

Biological Activity

Description Saracatinib (AZD0530) is a potent inhibitor of Src with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q).
Targets c-Src v-Abl        
IC50 2.7 nM 30 nM        


Cell experiment: [1]

Cell lines

A549 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

1 μM, 24 hours for cell migration inhibition 48 hours for cell invasion inhibition


A549 cells were grown to confluent monolayers, which were scratched with a pipette tip and incubated with AZD0530 at concentrations ranging from 100 to 1000 nM. DMSO treated control cells continuously migrated into the scratch and nearly closed the scratch within 24 hours. Cell migration was significantly inhibited by AZD0530 in a dose-dependent way. At the highest dose tested (1 μM), AZD0530 reduced A549 cell migration by more than 60%. Cell invasion was tested using a modified Matrigel assay with A549 cells. AZD0530 significantly reduced Matrigel invasion in A549 cells by 51%.

Animal experiment: [2]

Animal models

Female athymic nude mice injected with Panc410 cells

Dosage form

Oral administration, 50mg/kg/d for 28 days


AZD0530 administration clearly down-regulated Src, FAK, p-FAK, and pSTAT-3 expression in the sensitive tumor (Panc410) compared with control tumors. In addition, AZD0530 administration resulted in the down-regulation of XIAP as evidenced by the immunoblot of Panc410.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1] Purnell P R, Mack P C, Tepper C G, et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer, 2009, 4(4): 448.

[2] Rajeshkumar N V, Tan A C, De Oliveira E, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clinical Cancer Research, 2009, 15(12): 4138-4146.

Saracatinib (AZD0530) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Saracatinib (AZD0530) Molarity Calculator



Chemical Properties

Cas No. 379231-04-6 SDF Download SDF
Chemical Name N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
Formula C27H32ClN5O5 M.Wt 542.03
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Research Update

1. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer. 2013 Jan 1;132(1):224-35. doi: 10.1002/ijc.27649. Epub 2012 Jun 13.
Saracatinib is a dual Src/Abl inhibitor that inhibits ABCB1 transport function and hence reverses ABCB1-mediated MDR without affecting ABCB1 expression or AKT phosphorylation.
3. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013 Jan;12(1):16-26. doi: 10.1158/1535-7163.MCT-12-0109. Epub 2012 Nov 9.
Saracatinib is a c-Src/Abl kinase inhibitor that inhibited the growth and migration/invasion of gastric cancer cells through inhibiting a few signaling pathways, arresting cell cycle at G(1) phase and inducing Bim-mediated apoptosis. The combination of saracatinib with other chemotherapeutic agents exhibited enhanced anti-gastric cancer activities.
4. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. MAbs. 2014 Mar 1;6(2):403-8. doi: 10.4161/mabs.27443. Epub 2013 Dec 9.
The combination of trastuzumab and saracatinib, a SRC inhibitor, synergistically inhibited cell growth and potently reduced phosphorylation of Erb and AKT in both NCI-N87 and NCI-N87R gastric cancer cell lines.


Saracatinib (AZD0530) is a novel, potent Src family kinase (SFK)/Abl dual-kinase inhibitor with IC50 value of 2.7 nM [1].

Saracatinib has been reported to inhibit Src activation in DU145 and PC3 cell lines (prostate cancer cell lines). Both of c-Myc and cyclin D1 expression are decreased by Saracatinib. Saracatinib can inhibit the ERK1/2 and GSK3b phosphorylation as well as decrease β-catenin level in cells. Saracatinib inhibits the prostate tumor cell growth by inducing cycle arrest at G1/S phase. Saracatinib dose-dependently blocks cell migration in DU145 and PC3 cell lines [1].

In DU145 implanted orthotopic SCID mice model, treatment with Saracatinib has been demonstrated to down-regulate the Src expression as well as suppress the tumor size [1].

[1] Chang YM1, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene. 2008 Oct 23;27(49):6365-75.